CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The LungCARD project seeks to improve lung cancer diagnostics by developing a blood test that detects EGFR mutations in circulating tumor cells. This method aims to provide a faster and more reliable alternative to traditional biopsy techniques.
Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised medicine) – i.e., patients with mutation(s) in EGFR gene should receive a EGFR-Tyrosine Kinase Inhibitor (TKI) drug (e.g. afitinib) treatment; while those that do not present mutations in such gene, should be treated with chemotherapy.
Currently, the laboratories use PCR a…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Hull
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Malaga
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
GENETIKS SAGLIK HIZMETLERI TICARETLIMITED SIRKETI
Türkiye, Istanbul
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
